[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370277-105":59,"doc-detail-370277-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","navigating-metabolic-challenges-in-ovarian-cancer-insights-and-innovations-in-drug-repurposing","Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing","","Ovarian cancer is a highly lethal gynecological malignancy often diagnosed at advanced stages, where standard platinum chemotherapy faces major resistance and limited options. This review examines how metabolic reprogramming, shaped by metabolic syndrome, enhanced glycolysis, and altered lipid metabolism, fuels tumor progression, survival under hypoxia, and evasion of cell death. It also discusses repurposed metabolic-targeting drugs, including metformin and statins, and argues for future research to map metabolic networks to enable targeted therapies that improve outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/navigating-metabolic-challenges-in-ovarian-cancer-insights-and-innovations-in-drug-repurposing/370277/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/navigating-metabolic-challenges-in-ovarian-cancer-insights-and-innovations-in-drug-repurposing/370277.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is chemoresistance a major challenge in ovarian cancer?","Question",{"text":113,"@type":114},"Ovarian cancer commonly develops resistance to standard platinum-based chemotherapy, contributing to disease recurrence and poorer survival outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does metabolic reprogramming play in ovarian cancer progression?",{"text":118,"@type":114},"Metabolic reprogramming rewires glycolysis and lipid metabolism to support uncontrolled proliferation, survival under hypoxic conditions, and avoidance of cell death mechanisms.",{"name":120,"@type":111,"acceptedAnswer":121},"Which drug repurposing options are highlighted in this review?",{"text":122,"@type":114},"The review highlights metabolite-targeting repurposed drugs such as metformin and statins, which show promise in preclinical studies for disrupting altered metabolic pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370277,1790394939,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nNavigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing  \nSara Mikhael  | Georges Daoud   \nDepartment of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon Correspondence: Georges Daoud ([gd12@aub.edu.lb](gd12@aub.edu.lb))  \nReceived: 29 October 2024 | Revised: 16 January 2025 | Accepted: 30 January 2025  \nFunding: This work was supported by a grant from the American University of Beirut.  \nKeywords: drug repurposing strategy | metabolic reprogramming | metabolic syndrome | ovarian cancer  \nABSTRACT  \nBackground: Ovarian cancer (OC) is the most lethal gynecological malignancy and a major global health concern, often diagnosed at advanced stages with poor survival rates. Despite advancements in treatment, resistance to standard chemotherapy remains a critical challenge with limited treatment options available. In recent years, the role of metabolic reprogramming in OC has emerged as a key factor driving tumor progression, therapy resistance, and poor clinical outcomes.  \nMethods: This review explores the intricate connections between metabolic syndrome, enhanced glycolysis, and altered lipid metabolism within OC cells, which fuel the aggressive nature of the disease. We discuss how metabolic pathways are rewired in OC to support uncontrolled cell proliferation, survival under hypoxic conditions, and evasion of cell death mechanisms, positioning metabolic alterations as central to disease progression. The review also highlights the potential of repurposed metabolictargeting drugs, such as metformin and statins, which have shown promise in preclinical studies for their ability to disrupt these altered metabolic pathways.  \nConclusion: Drug repurposing offers a promising strategy to overcome chemoresistance and improve patient outcomes. Future research should focus on unraveling the complex metabolic networks in OC to develop innovative, targeted therapies that can enhance treatment efficacy and patient survival.  \n1 | Ovarian Cancer Overview  \nWhen fatal malignancies in women come to mind, one inherently thinks of breast cancer. Pink ribbons fill the month of October, packed with awareness campaigns, posters, flyers, rallies, and screening procedures. Nevertheless, Ovarian Cancer (OC) stands as the most lethal gynecological malignancy, ranking among the top five leading causes of cancer-related deaths in women globally [1, 2] . OC diagnosis predominantly relies on the pathological analysis of a biopsy [3] . It exhibits diverse genetic patterns and substantial phenotypic heterogeneity [4] . According to the 5th edition of the WHO guidelines updated in 2020, Ovarian Neoplasms are classified as Epithelial tumors, Mesenchymal tumors, Mixed epithelial and mesenchymal  \ntumors, Germ cell tumors, sex-cord stromal tumors, miscellaneous tumors, tumor-like lesions, and Secondary tumors. This classification closely aligns with the 4th edition [5, 6] .  \nThe prognosis of OC is intricately tied to various factors, with the stage at initial diagnosis being a critical determinant. If OCis diagnosed at an early stage where the tumor is restricted to the ovaries (Stage I), the 5-year OS reaches around 90%[2, 7] . Progression to Stage II, characterized by tumor extension to the pelvic region, is associated with a 5-year OS rate of 70% . However, the survival rate drops sharply to 20% if OC is diagnosed in stages III or IV, where the disease has advanced beyond the pelvic area. However, even with advancements in treatment modalities, the emergence of treatment resistance poses a  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2025; 14:e70681 1 of 19  \n[http","cbCaiuk4XlQBkWog","https://ap.wps.com/l/cbCaiuk4XlQBkWog","pdf",1962200,"English","# Ovarian Cancer Overview\n## Challenges in Therapy\n### Metabolic Syndrome\n#### Obesity","[{\"question\":\"Why is chemoresistance a major challenge in ovarian cancer?\",\"answer\":\"Ovarian cancer commonly develops resistance to standard platinum-based chemotherapy, contributing to disease recurrence and poorer survival outcomes.\"},{\"question\":\"What role does metabolic reprogramming play in ovarian cancer progression?\",\"answer\":\"Metabolic reprogramming rewires glycolysis and lipid metabolism to support uncontrolled proliferation, survival under hypoxic conditions, and avoidance of cell death mechanisms.\"},{\"question\":\"Which drug repurposing options are highlighted in this review?\",\"answer\":\"The review highlights metabolite-targeting repurposed drugs such as metformin and statins, which show promise in preclinical studies for disrupting altered metabolic pathways.\"}]","Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing | PDF",1790187721,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3010fa05102b96e39461a11ab5b97487.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6f6d897125e6f60de65c392f31dfcce.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4b9dd1c65adc48201a01994224eff56.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3aaa6b54d5243db93e0985fc10eeec6a.webp",980,1287]